195 related articles for article (PubMed ID: 12324556)
1. An economic evaluation of activated protein C treatment for severe sepsis.
Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
6. [Medical-economic evaluation of severe sepsis].
Guidet B
Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
[No Abstract] [Full Text] [Related]
7. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
Chawla LS; Seneff MG; Nelson DR; Williams M; Levy H; Kimmel PL; Macias WL
Clin J Am Soc Nephrol; 2007 Jan; 2(1):22-30. PubMed ID: 17699383
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of activated protein C in real-life clinical practice.
Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of drotrecogin alfa (activated).
Tsitanidis J
Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
Riou França L; Launois R; Le Lay K; Aegerter P; Bouhassira M; Meshaka P; Guidet B
Int J Technol Assess Health Care; 2006; 22(1):101-8. PubMed ID: 16673686
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Green C; Dinnes J; Takeda AL; Cuthbertson BH
Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
[TBL] [Abstract][Full Text] [Related]
18. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
Dasta JF; Cooper LM
Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
[TBL] [Abstract][Full Text] [Related]
19. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.
Lowry SF; Awad S; Ford H; Cheadle W; Williams MD; Qualy RL; McCollam JS; Bates BM; Fry DE;
Surg Infect (Larchmt); 2004; 5(3):261-8. PubMed ID: 15684797
[TBL] [Abstract][Full Text] [Related]
20. The costs and cost-effectiveness of an integrated sepsis treatment protocol.
Talmor D; Greenberg D; Howell MD; Lisbon A; Novack V; Shapiro N
Crit Care Med; 2008 Apr; 36(4):1168-74. PubMed ID: 18379243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
